SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bruce Rosen who wrote (554)9/17/1997 12:41:00 PM
From: Tokyo VD   of 7041
 
Well, I'm going to put my money where my mouth is.

Bruce, you said that " Open label studies confirm that about 25 to 30% of men continue to get significant benefits over the long term and remain as regular users." If this is regarding Vasomax, it is impossible because Vasomax open label studies have not yet been reported (enrollment is not yet complete).

You also said, "In the U.S. phase 3 trials, 98% of the men tested had organic causes, with some suffering from heart disease, diabetes and other ailments. The only excluded causes were severe spinal cord injuries and radical prostectomies. Zonagen actually screened a more severely impotent population than Pfizer." But if you asked any investigator they would tell you that the patient population was mild-to-moderate, not severe like Vivus or Pharmacia-Upjohn.

If this stock rises a little, I'm willing to put my wallet where my mouth is.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News